Mechanisms linking brain insulin resistance to alzheimer’s disease;Mecanismos que ligam a resistência insulínica cerebral à doença de alzheimer: Uma breve revisão

Dementia e Neuropsychologia

Volumn 9, Issue 2, 2015, Pages 96-102

  Matioli, Maria Niures P S ^a   Nitrini, Ricardo ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Alzheimer s disease; Diabetes mellitus; Insulin resistance; Mechanisms; Neurodegeneration

Indexed keywords

EID: 84934291396     PISSN: 19805764     EISSN: None     Source Type: Journal    
DOI: 10.1590/1980-57642015DN92000003     Document Type: Article

References (92)

1. World Health Organization. Dementia: a public health priority. WHO Library 2012.
2. International Diabetes Federation, sixth edition. Diabetes Atlas, 2014. www.idf.org/diabetesatlas.
3. Janson J, Laedtke T, Parisi JE, O’Brien P, Petersen RC, Butler PC. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 2004; 53:474-481.
4. Duyckaerts C, Delatour B, Potier MC. Classifcation and basic pathology of Alzheimer disease. Acta Neuropathol 2009;118:5-36.
5. de la Monte S M and Tong M. Brain metabolic dysfunction at the core of Alzheimer’s disease. Biochem Pharmacol 2014;88:548-559.
6. Robakis NK. Mechanisms of AD neurodegeneration may be independent of Abeta and its derivatives. Neurobiol Aging 2011;32:372-9.
7. Wu L, Rosa-Neto P, Hsiung G Y, et al. Early-onset familial Alzheimer’s disease (EOFAD). Can J Neurol Sci 2012;39:436-445.
8. Bosco D, Fava A, Plastino M, Montalcini T, Pujia A. Possible implications of insulin resistance and glucose metabolism in Alzheimer’s disease pathogenesis. J Cell Mol Med 2011;15:1807-1821.
9. Biessels GJ, Staekenborg S, Brayne C and Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 2006; 5:64-74.
10. Arab L, Sadeghi R, Walker DG, Lue LF and Sabbagh MN. Consequences of Aberrant Insulin Regulation in the Brain: Can Treating Diabetes be Effective for Alzheimer’s Disease. Curr Neuropharmacol 2011;9:693-705.
11. Leibson CL, Rocca WA, Hanson VA, et al. Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am J Epidemiol 1997;145:301-308.
12. Brayne C, Gill C, Huppert FA, et al. Vascular risks and incident dementia: results from a cohort study of the very old. Dement Geriatr Cogn Disord 1998;9:175-180.
13. Ott A, Stolk R P, van Harskamp F, et al. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 1999;53:1937-1942.
14. Arvanitakis Z, Wilson RS, Bienias JL, et al. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 2004;61:661-666.
15. Luchsinger JA, Reitz C, Honig LS, et al. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology 2005;654:545-551.
16. Whitmer RA, Sidney S, Selby J, et al. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 2005;64:277-281.
17. Cheng D, Noble J, Tang MX, et al. Type 2 diabetes and late-onset Alzheimer’s disease. Dement Geriatr Cogn Disord 2011;31:424-430.
18. Arvanitakis Z, Schneider JA, Wilson RS, at al. Diabetes is related to cerebral infarction but not AD pathology in older persons. Neurology 2006;67:1960-5.
19. Heitner J, Dickson D. Diabetes do not have increased Alzheimer’ type pathology compared with age-matched controls subjects. A retro-spective postmortem immunocytochemical and hisfuorescence study. Neurology 1997;49:1306-11.
20. Beeri MS, Silverman JM, Davis KL, et al. Type 2 Diabetes Is Negatively Associated with Alzheimer’s disease Neuropathology. J Gerontol A Biol Sci Med Sci 2005;60:471-475.
21. Alafuzoff I, Aho L, Helisalmi S, Mannermaat A, Soininen H. β-Amyloid deposition in brains of subjects with diabetes. Neuropathol Appl Neuro-biol 2009;35:60-68.
22. Nelson PT, Smith CD, Abner EA, et al. Human cerebral neuropathology of Type 2 diabetes mellitus. Biochimica et Biophysica Acta 2009; 1792:454-469.
23. Ahtiluoto S, Polvikoski T, Peltonen M, et al. Diabetes, Alzheimer disease, and vascular dementia: a population-based neuropathological study. Neurology, 2010;75:1195-1202.
24. Watson GS, Cholerton BA, Reger MA, et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 2005;13:950-958.
25. Risner ME, Saunders AM, Altman JF, et al. Effcacy of rosiglitazone in a genetically defned population with mild-to-moderate Alzheimer’s disease. Pharmacogenomics J 2006;6:246-254.
26. Roses AD. Commentary on “a roadmap for the prevention of dementia: the inaugural Leon Thal Symposium.” An impending prevention clinical trial for Alzheimer’s disease: roadmaps and realities. Alzheimers Dement 2008;4:164-166.
27. Reger MA, Watson GS, Green PS, et al. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 2008;70:440-448.
28. Sato T, Hanyu H, Hirao K, et al. Effcacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging 2011;32:1626-1633.
29. Bornstein NM, Brainin M, Guekht A, et al. Diabetes and the brain: issues and unmet needs. Neurol Sci 2014;35:995-1001.
30. Yu Y, Kastin AJ, Pan W. Reciprocal interactions of insulin and insulin-like growth factor I in receptor-mediated transport across the blood-brain barrier. Endocrinology 2006;147:2611-2615.
31. Roth RA, Morgan DO, Beaudoin J, Sara V. Purifcation and characterization of the human brain insulin receptor. J Biol Chem 1986;261:3753-3757.
32. Kotzke G, Schutt M, Missler U, et al. Binding of human, porcine and bovine insulin to insulin receptors from human brain, muscle and adipocytes and to expressed recombinant alternatively spliced insulin receptor isoforms. Diabetologia 1995;38:757-763.
33. Pardrige WM, Eisenberg J and Yang J. Human blood-brain barrier insulin growth factor type 1 receptor signaling in the cells of oligoden-drocyte lineage is required for normal in vivo oligodendrocyte development and myelination. receptor. J Neurochem 1985;44:1771-1778.
34. de la Monte SM, Wands JR. Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer’s disease. J Alzheimers Dis 2005;7:45-61.
35. Zeger M, Popken G, Zhang J, Xuan S, Lu QR, Schwab MH, et al. Insulin-like Glia 2007;55:400-11.
36. Freude S, Schilbach K, Schubert M. The role of IGF-1 receptor and insulin receptor signaling for the pathogenesis of Alzheimer’s disease: from model organisms to human disease. Curr Alzheimer Res 2009; 6:213-223.
37. de la Monte SM, Longato L, Tong M, Wands JR. Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and nonalcoholic steatohepatitis. Curr Opin Investig Drugs 2009;10:1049-1060.
38. de la Monte SM (b). Brain Insulin Resistence and Defciency as Therapeutic Targets in Alzheimer’s Disease. Curr Alzheimer Res 2012;9:35-66.
39. D’Ercole AJ, Ye P. Expanding the mind: insulin-like growth factor I and brain development. Endocrinology 2008;149:5958-5962.
40. Steen E, Terry BM, Rivera EJ, et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease--is this type 3 diabetes? J Alzheimers Dis 2005;7:63-80.
41. Caselli RJ, Chen K, Lee W, et al. Correlating cerebral hypometabolism with future memory decline in subsequent converters to amnestic pre-mild cognitive impairment. Arch Neurol 2008;65:1231-1236.
42. Mosconi L, Pupi A, De Leon MJ. Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer’s disease. Ann N Y Acad Sci 2008;1147:180-95.
43. Mosconi L, Mistur R, Switalski R, et al. FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verifed Alzheimer’s disease. Eur J Nucl Med Mol Imaging 2009;36:811-822.
44. Langbaum JB, Chen K, Caselli RJ, et al. Hypometabolism in Alzheimer-affected brain regions in cognitively healthy Latino individuals carrying the apolipoprotein E epsilon4 allele. Arch Neurol 2010;67:462-468.
45. Rivera EJ, Goldin A, Fulmer N, et al. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer’s disease: link to brain reductions in acetylcholine. J Alzheimers Dis 2005; 8:247-268.
46. de la Monte SM, Tong M, Bowling N, Moskal P. si-RNA inhibition of brain insulin or insulin-like growth factor receptors causes developmental cerebellar abnormalities: relevance to fetal alcohol spectrum disorder. Mol Brain 2011;4:13.
47. Goh SY, Cooper ME. Clinical review: role of advanced glycation end products in progression and complications of diabetes. J Clin Endo-crinol Metab 2007;93:1143-1152.
48. Takuma K, Fung F, Zhanf W, et al. RAGE-mediated signaling contributes to intraneuronal transport of amyloid-beta and neuronal dysfunction. Proc Natl Acad Sci U S A 2009;106:20021-20026.
49. Ahmad W. Overlapped Metabolic and Therapeutic Links between Alzheimer and Diabetes. Mol Neurobiol 2013;47:399-424.
50. Srikanth V, Maczurek A, Phan T, et al. Advanced glycation endprod-ucts and their receptor RAGE in Alzheimer’s disease. Neurobiol Aging. 2011;32:763-777.
51. Naka Y, Bucciarelli LG, Wendt T, et al. RAGE axis: Animal models and novel insights into the vascular complications of diabetes. Arterioscler Thromb Vasc Biol 2004;24:1342-1349.
52. Bucciarelli LG, Wendt T, Rong L, et al. RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cell Mol Life Sci 2002;59:1117-1128.
53. Jeynes B, Provias J. Evidence for altered LRP/RAGE expression in Alzheimer lesion pathogenesis. Curr Alzheimer Res 2008;5:432-437.
54. Miller MC, Tavares R, Johanson CE, et al. Hippocampal RAGE immu-noreactivity in early and advanced Alzheimer’s disease. Brain Res 2008; 1230:273-280.
55. Lue LF, Yan SD, Stern DM, Walker DG. Preventing activation of receptor for advanced glycation endproducts in Alzheimer’s disease. Curr. Drug Targets. CNS. Neurol Disord 2005;4:249-266.
56. Lue LF, Walker DG, Jacobson S, Sabbagh M. Receptor for advanced glycation end products: its role in Alzheimer’s disease and other neurological diseases. Future Neurol 2009;4:167-177.
57. Hudson BI, Wendt T, Bucciarelli LG, et al. Diabetic vascular disease: it’s all the RAGE. Antioxid. Redox Signal 2005;7:1588-1600.
58. Jandeleit-Dahm K, Watson A, Soro-Paavonen A. The AGE/RAGE axis in diabetes-accelerated atherosclerosis. Clin Exp Pharmacol Physiol 2008;35:329-334.
59. Yamagishi S, Nakamura K, Matsui T, et al. Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications. Expert Opin Investig Drugs 2008;17:983-996.
60. Deane R, Bell RD, Sagare A, Zlokovic BV. Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer’s disease. CNS Neurol Disord Drug Targets. 2009;8:16-30.
61. Giri R, Selvaraj S, Miller CA, et al. Effect of endothelial cell polarity on beta-amyloid-induced migration of monocytes across normal and AD endothelium. Am J Physiol Cell Physiol 2002;283:C895-C904.
62. Korf ES, White LR, Scheltens P, Launer LJ. Brain aging in very old men with type 2 diabetes: the Honolulu-Asia aging study. Diabetes Care 2006;29:2268-2274.
63. Chen GJ, Xu J, Lahousse AS, et al. Transient hypoxia causes Alzheimer-type molecular and biochemical abnormalities in cortical neurons: potential strategies for neuroprotection. J Alzheimers Dis 2003;5:209-228.
64. Hoyer S, Lannert H. Inhibition of the neuronal insulin receptor causes Alzheimer-like disturbances in oxidative/energy brain metabolism and in behavior in adult rats. Ann N Y Acad Sci 1999;893:301-303.
65. de la Monte SM, Wands JR. Chronic gestational exposure toethanol impairs insulin-stimulated survival and mitochondrial function in cere-bellar neurons. Cell Mol Life Sci 2002;59:882-893.
66. Hoyer S, Lee SK, Loffer T, Schliebs R. Inhibition of the neuronal insulin receptor. An in vivo model for sporadic Alzheimer disease? Ann N Y Acad Sci 2009;920:256-258.
67. de la Monte, Suzanne M. Contributions of Brain Insulin Resistance and Defciency in Amyloid-Related Neurodegeneration in Alzheimer’s Disease. Drugs 2012;72:49-66.
68. Qiu WQ, Walsh DM, Ye Z, Vekrellis K, et al. Insulindegrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem 1998;273:32730-32738.
69. Ling Y, Morgan K, Kalsheker N. Amyloid precursor protein (APP) and biology of proteolytic processing: relevance to Alzheimer’s disease. International Journal of Biochemistry and Cell Biology 2003;35: 1505-1535.
70. Schuh AF, Rieder CM, Rizzi L, Chaves M, Roriz-Cruz M. Mechanisms of brain aging regulation by insulin: implications for neurodegeneration in late-onset Alzheimer’s disease. ISRN Neurol 2011;2011:306905.
71. Williamson R, McNeilly A, Sutherland C. Insulin resistence in the brain: an old-age or new-age problem? Bioch Pharmacol 2012;84:737-45.
72. Farris W, Mansourian S, Chang Y, et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A 2003;100:4162-4167.
73. Whitmer RA. Type 2 diabetes and risk of cognitive impairment and dementia. Curr Neurol Neurosci Rep 2007;7:373-380.
74. Watson GS, Peskind ER, Asthana S, et al. Insulin increases CSF Abeta42 levels in normal older adults. Neurology 2003;60:1899-903.
75. Gasparini L, Netzer WJ, Greengard P, Xu H. Does insulin dysfunction play a role in Alzheimer’s disease. Trends Pharmacol Sci 2002;23:288-93.
76. Messier C, Teutenberg K. The role of insulin, insulin growth factor, and insulin-degrading enzyme in brain aging and Alzheimer’s disease. Neural Plast 2005;12:311-328.
77. Xie L, Helmerhorst E, Taddei K, Plewright B, Van Bronswijk W, Martins R. Alzheimer’s beta-amyloid peptides compete for insulin binding to the insulin receptor. J Neurosci 2002;22:RC221.
78. Phiel CJ, Wilson CA, Lee VM, Klein PS. GSK-3alpha regulates production of Alzheimer’s disease amyloid-beta peptides. Nature 2003;423: 435-439.
79. Takashima A. Amyloid-beta, tau, and dementia. J Alzheimers Dis 2009;17:729-736.
80. Schubert M, Brazil D P, Burks DJ, et al. Insulin receptor substrate-2 defciency impairs brain growth and promotes tau phosphorylation. J Neurosci 2003;23:7084-7092
81. Schubert M, Gautam D, Surjo D, et al. Role for neuronal insulin resistance in neurodegenerative diseases. Proc Natl Acad Sci U S A 2004; 101:3100-3105.
82. de la Monte SM, Chen GJ, Rivera E, Wands JR. Neuronal thread protein regulation and interaction with microtubule-associated proteins in SH-Sy5y neuronal cells. Cell Mol Life Sci 2003;60:2679-2691.
83. Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multitasking kinase. J Cell Sci 2003;116:1175-1186.
84. Fraser PE, Yu G, Levesque L, et al. Presenilin function: connections to Alzheimer’s disease and signal transduction. Biochem Soc Symp 2001;67:89-100.
85. Grilli M, Ferrari Toninelli G, Uberti D, et al. Alzheimer’s disease linking neurodegeneration with neurodevelopment. Funct Neurol 2003;18: 145-148.
86. Bhat R, Xue Y, Berg S, et al. Structural insights and biological effects of glycogen synthase kinase 3-specifc inhibitor AR-A014418. J Biol Chem 2003;278:45937-45945.
87. Lebouvier T, Scales TM, Williamson R, et al. The microtubule-associ-ated protein tau is also phosphorylated on tyrosine. J Alzheimers Dis 2009;18:1-9.
88. Morales I, Farias G, Maccioni RB. Neuroimmunomodulation in the patho-genesis of Alzheimer’s disease. Neuroimmunomodulation 2010; 17: 202-204.
89. Hanger D P, Seereeram A, Noble W. Mediators of tau phosphoryla-tion in the pathogenesis of Alzheimer’s disease. Expert Rev Neurother 2009;9:1647-1666.
90. Iqbal K, Liu F, Gong CX, Alonso Adel C, Grundke-Iqbal I. Mechanisms of tau-induced neurodegeneration. Acta Neuropathol 2009;118: 53-69.
91. Ling X, Martins RN, Racchi M, et al. Amyloid beta antogonizes insulin promoted secretion of the amyloid beta protein precursor. J Alzheimers Dis 2002;4:369-374.
92. Zheng WH, Kar S, Quiron R. Insulin-like growth fator-1 (IGF-1): a neuro-protective trophic fator acting via the AKT Kinase pathway. J Neurol Transm Suppl 2000;60:61-272.